Belgian authorities suspended the vaccination of Janssen, Johnson & Johnson’s vaccine for children under 41 years old, on Wednesday because a woman died after receiving the vaccine.
The public health department said in a statement: “The inter-ministerial meeting decided to temporarily suspend the Janssen vaccination for citizens under 41 years old until a more detailed analysis of the benefits and risks of the EMA (European Medicines Agency).”
A woman under the age of 40 died on May 21. The statement stated that she was previously hospitalized due to severe thrombosis and platelet deficiency.
She was vaccinated outside the official vaccination campaign by her employer and Belgium.
The statement said that so far, 40,000 doses of Janssen drugs have arrived in Belgium, and 80% of the drugs have been injected over 45 years of age.
Johnson & Johnson announced on April 20 that it would resume delivery of vaccines to the European Union, but after requiring some countries/regions, including Belgium, to temporarily suspend vaccination due to rare blood clots after vaccination, a warning was posted on the label. .
The company claims that it has not established a clear causal relationship between blood clots and vaccines, and EMA points out that the benefits outweigh the risks.
The Janssen vaccine is available as a single dose and is mainly used in Belgium to vaccinate the elderly and their vulnerable groups (such as the homeless and undocumented immigrants).
Belgium has sought advice from the EMA to assess the link between the woman’s death and Johnson & Johnson’s vaccine, but did not disclose it when hoping for the final opinion of the European agency.